Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ: TVTX )

20.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
The Latest Analyst Ratings for Travere Therapeutics
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Expert Ratings for Travere Therapeutics
Via Benzinga
Analyst Ratings for Travere Therapeutics
Via Benzinga
11 Analysts Have This to Say About Travere Therapeutics
Via Benzinga
3 Small-Cap Stocks That Could Be Big-Time Winners
These stocks come with significant risks. But they could generate huge returns over time. 
Via The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
Travere Therapeutics shares have lost nearly 30% since early May. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Travere Therapeutics to Report Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Recap: Travere Therapeutics Q1 Earnings
Via Benzinga
Earnings Outlook For Travere Therapeutics
Via Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks With Blockbuster Potential
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports First Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.